en · de · es · pt
methods-notes.peptides4800.com › Data › Tb-500 Background And Identity — Beginner to Advanced

Tb-500 Background And Identity — Beginner to Advanced

By Editorial Desk · published 2025-12-12 · last reviewed 2026-01-03 · Data

A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-01-03 and is reviewed periodically as new material appears.

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

Detection, Stability, and Regulatory Status

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Tb-500 at a glance

PropertyValueNotes
AppearanceWhite to off-white lyophilized powderTypical form for short synthetic peptides
Solubility classFreely soluble in water and aqueous bufferDissolution aided by gentle mixing, not vigorous shaking
Typical storage temperature−20 °C, desiccated−80 °C used for long-term holding
Common analytical methodReverse-phase HPLC with UV detection near 214 nmIdentity confirmed separately by mass spectrometry
Common synonymsThymosin beta-4 fragment; TB4 fragmentNaming varies between suppliers and publications

Research Framing and Evidence Base

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Related pages on this site

Handling, Storage, and Quality Control

Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.

Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.

Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.

Handling, Storage and Quality Checks

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Background from the literature

== Conjugates == Attaching other hormones such as estrogen, thyroid hormone (T3), and dexamethasone to GLP-1 or glucagon restrict the activity of the attached hormone to cells that express GLP-1 or glucagon. GLP-1 and amylin receptor agonist conjugates have also been tested in preclinical trials.

Nicotine is a very hygroscopic, colorless to pale yellow, oily liquid that gradually turns brown on exposure to air or light. It develops a characteristic pungent, fishy odor of pyridine and has an acrid burning taste. Pure nicotine tastes "terrible". It is very soluble in alcohol, chloroform, ether, light petroleum, kerosene, or oils. It is miscible with water in its neutral amine base form between 60 °C and 210 °C. It is a dibasic nitrogenous base, having Kb1=1×10−6, Kb2=1×10−11. It readily forms ammonium salts with acids that are usually solid and water-soluble. Its flash point is 95 °C, and its auto-ignition temperature is 244 °C. Nicotine is volatile (vapor pressure 5.5 Pa at 25 °C) On exposure to ultraviolet light or various oxidizing agents, nicotine is converted to nicotine oxide, nicotinic acid (niacin, a B3 vitamer), and methylamine. Anabasine is a structural isomer of nicotine, as both compounds have the molecular formula C10H14N2.

=== Other musculoskeletal === A 2014 Cochrane review of musculoskeletal injuries found very weak evidence for a decrease in pain in the short term, and no difference in function in the short, medium or long term. It has not been shown to be useful for bone healing. A 2016 review of bone graft augmentation found only one study reporting a difference in bone augmentation, while four studies found no difference. As compared to other conservative treatments for non-surgical orthopedic illnesses (e.g. steroid injection for plantar fasciitis), evidence does not support the use of PRP as a conservative treatment. A 2018 review found that evidence was lacking for Achilles tendinopathy. A 2019 meta-analysis found that, for most outcomes in Achilles tendinopathy, PRP treatment did not differ from placebo treatment. A 2019 study conducted an umbrella review that "considered studies that included populations with differing levels of physical activity, including studies on the sporting population (professional and/or recreational athletes) and studies didn't explicitly mention involving a sporting population." This inquiry reported only poor quality evidence that PRP offers any clinical benefits for treatment in acute muscle, tendon, and ligament injuries in any population.

Research into the cause of the disease began in 1868, when grape growers in Roquemaure, near Pujaut, asked the agricultural society in Montpellier for help. The society appointed a committee including botanist Jules Émile Planchon, local grower Felix Sahut, and the society's president, Gaston Bazille. Sahut soon noticed that the roots of dying vines were infested with "lice" which were sucking sap from the plants. The committee named the new insect Rhizaphis vastatrix. Planchon consulted French entomologists Victor Antoine Signoret and Jules Lichtenstein (Planchon's brother-in-law). Signoret suggested renaming the insect Phylloxera vastatrix, due to its similarity to Phylloxera quercus, which afflicted oak leaves. In 1869, English entomologist John Obadiah Westwood suggested that an insect that had afflicted grape leaves in England circa 1863 was the same insect afflicting grape vines' roots in France. Also in 1869, Lichtenstein suggested that the French insect was an American "vine louse" that had been identified in 1855 by the American entomologist Asa Fitch, which he had named Pemphigus vitifoliae. However, there was a problem with these suggestions: French grape lice were known to infest only a vine's roots, whereas American grape lice were known to infest only its leaves. The British-born American entomologist Charles Valentine Riley had been following news of the outbreak in France.

Elton John plays the final UK concert of his farewell tour at Glastonbury 2023, headlining the Pyramid Stage on the festival's final day. 26 June A two-year BBC investigation into the 1993 murder of Stephen Lawrence identifies a sixth suspect who was not charged at the time and is now deceased. Banking giant HSBC announces that it will vacate its 45-storey tower at 8 Canada Square in Canary Wharf and establish a smaller headquarters, possibly in the City of London, when its current lease expires in 2027. The move is attributed to an increase in remote work and less need for in-person office work. Prince William and Geri Horner announce the launch of Homewards, a five-year project aimed at reducing the number of homeless people in the UK. The National Cancer Research Institute announces that it will be closing, amid concerns over its funding. 27 June Boots announces plans to close 300 of its outlets over the next years, saying it will close stores in close proximity to other branches. A report compiled by the Independent Commission for Equity in Cricket (ICEC) says racism, sexism, classism and elitism are "widespread" in English and Welsh cricket. 28 June Daniel Korski withdraws as the Conservative Party's candidate for the 2024 London mayoral election after being accused of groping by novelist and TV producer Daisy Goodwin. A BBC News investigation finds that paedophiles are using Stable Diffusion, a piece of artificial intelligence software, to create lifelike images of child sexual abuse, which are then being distributed through platforms such as Patreon.

Sources: en.wikipedia.org

Reference notes

React the peptide with a reagent that will selectively label the terminal amino acid. Hydrolyse the protein. Determine the amino acid by chromatography and comparison with standards. There are many different reagents which can be used to label terminal amino acids. They all react with amine groups and will therefore also bind to amine groups in the side chains of amino acids such as lysine - for this reason it is necessary to be careful in interpreting chromatograms to ensure that the right spot is chosen. Two of the more common reagents are Sanger's reagent (1-fluoro-2,4-dinitrobenzene) and dansyl derivatives such as dansyl chloride. Phenylisothiocyanate, the reagent for the Edman degradation, can also be used. The same questions apply here as in the determination of amino acid composition, with the exception that no stain is needed, as the reagents produce coloured derivatives and only qualitative analysis is required. So the amino acid does not have to be eluted from the chromatography column, just compared with a standard. Another consideration to take into account is that, since any amine groups will have reacted with the labelling reagent, ion exchange chromatography cannot be used, and thin-layer chromatography or high-pressure liquid chromatography should be used instead.

=== In prokaryotes === In prokaryotes a small 30S ribosomal subunit contains the 16S ribosomal RNA. The large 50S ribosomal subunit contains two rRNA species (the 5S and 23S ribosomal RNAs). Therefore it can be deduced that in both bacteria and archaea there is one rRNA gene that codes for all three rRNA types :16S, 23S and 5S. Bacterial 16S ribosomal RNA, 23S ribosomal RNA, and 5S rRNA genes are typically organized as a co-transcribed operon. As shown by the image in this section, there is an internal transcribed spacer between 16S and 23S rRNA genes. There may be one or more copies of the operon dispersed in the genome (for example, Escherichia coli has seven). Typically in bacteria there are between one and fifteen copies. Archaea contains either a single rRNA gene operon or up to four copies of the same operon. The 3' end of the 16S ribosomal RNA (in a ribosome) recognizes a sequence on the 5' end of mRNA called the Shine-Dalgarno sequence.

For a compound to reach a tissue, it usually must be taken into the bloodstream – often via mucous surfaces like the digestive tract (intestinal absorption) – before being taken up by the target cells. Factors such as poor compound solubility, gastric emptying time, intestinal transit time, chemical instability in the stomach, and inability to permeate the intestinal wall can all reduce the extent to which a drug is absorbed after oral administration. Absorption critically determines the compound's bioavailability. Drugs that absorb poorly when taken orally must be administered in some less desirable way, like intravenously or by inhalation (e.g. zanamivir). Routes of administration are an important consideration.

== Pharmacokinetics == Maximum decrease in blood pressure occurs 4–6 hours after oral dosage. The half-life of methyldopa is 105 minutes. Methyldopa exhibits variable absorption from the gastrointestinal tract. It is metabolized in the liver and intestines and is excreted in urine.

Wild yeast populations can be incredibly diverse and commonly include species of Saccharomyces, Candida, Pichia, Hanseniaspora and Metschnikowia. Typically, the native yeast take up residence in the cidery, and can be important to the unique flavour of the product. Although it was once believed that the native yeast carrying out these spontaneous fermentations also came from the orchard itself, research has shown that the microbes cultured from apples in the orchard do not align with the microbes found during the various stages of fermentation, suggesting that the sole source of native yeast is the cidery. Indigenous yeast strain population dynamics are affected by climatic conditions, apple variety, geographic location, and cider making technologies used. These variables cause different regions to host unique endemic yeast populations. The particular composition of endemic yeast strains and the yeast's activity during fermentation are responsible for the unique characteristics of ciders produced in certain regions. Unique autochthonous yeast populations promote different compositions of volatile flavour compounds, which form distinct tastes, aromas, and mouthfeel in finished ciders. Using wild yeast populations for fermentation introduces variability to the cider making process that makes it more difficult to generate multiple batches of cider that retain consistent characteristics. Aside from carrying out the primary fermentation of cider, yeast may also play other roles in cider production.

Sources: en.wikipedia.org

Notes from published material

== History == Historically, ligand binding assay techniques were used extensively to quantify hormone or hormone receptor concentrations in plasma or in tissue. The ligand-binding assay methodology quantified the concentration of the hormone in the test material by comparing the effects of the test sample to the results of varying amounts of known protein (ligand). The foundations for which ligand binding assay have been built are a result of Karl Landsteiner, in 1945, and his work on immunization of animals through the production of antibodies for certain proteins. Landsteiner's work demonstrated that immunoassay technology allowed researchers to analyze at the molecular level. The first successful ligand binding assay was reported in 1960 by Rosalyn Sussman Yalow and Solomon Berson. They investigated the binding interaction for insulin and an insulin-specific antibody, in addition to developing the first radioimmunoassay (RIA) for insulin. These discoveries provided precious information regarding both the sensitivity and specificity of protein hormones found within blood-based fluids. Yalow and Berson received the Nobel Prize in Medicine as a result of their advancements. Through the development of RIA technology, researchers have been able to move beyond the use of radioactivity, and instead, use liquid- and solid-phase, competitive, and immunoradiometric assays. As a direct result of these monumental findings, researchers have continued the advancement of ligand binding assays in many facets in the fields of biology, chemistry, and the like.

==== Efficacy against Russia ==== Academic Jeremy Garlick writes that sanctions against Russia have, at least in the short term, backfired both economically and geopolitically, benefiting Russia's economy and bringing Russia and China closer together. Following the Russian invasion of Ukraine, Asian countries—primarily China and India—absorbed an increasing share of Russian oil and gas. Because Russian imports from the West declined after sanctions, Russia's trade balance rose sharply, increasing cash reserves. By June 2022, the Russian ruble had risen sharply and was among the world's best-performing currencies. In October 2025, the United States imposed sanctions against Russia's largest oil companies Rosneft and Lukoil, and threatened secondary sanctions against foreign financial institutions and companies continuing to do business with them, with particular implications for customers in China and India.

Skin care interventions consist of applying one or more products to specific areas of the skin in a specific order. A skin care routine may consist of cleansing, exfoliation, toning, targeted treatment, and moisturizing. Instructions for how much to use, how often, and for how long are not always clear.

Elagolix is taken by the oral route of administration, in contrast to other GnRH modulators. The oral bioavailability of elagolix in humans is not described in the Food and Drug Administration (FDA) label for the medication, but in animal research elagolix showed a low oral bioavailability of 5.8% in rats and 11% in monkeys. Following administration, elagolix is rapidly absorbed, with peak concentrations occurring after 0.5 to 1.5 hours. The drug accumulation ratio of elagolix at 150 mg once per day is 0.98 and at 200 mg twice per day is 0.89, indicating that it is not accumulated in the body with continuous administration. At steady state, peak levels of elagolix at 150 mg once per day are 574 ng/mL and at 200 mg twice per day are 774 ng/mL while area-under-the-curve levels of elagolix at 150 mg once per day are 1,292 ng•hour/mL and at 200 mg twice per day are 1,725 ng•hour/mL. A toxicology study found that levels of elagolix in women after a single dose of 1,200 mg were 17 times higher than in women taking 200 mg twice daily. Taking elagolix with a high-fat meal has been found to decrease its peak levels by 36% and its area-under-the-curve levels by 24%. In terms of distribution, the plasma protein binding of elagolix is 80% and its blood-to-plasma ratio is 0.6. The volume of distribution at steady state is 1,674 L at 150 mg once per day and 881 L at 200 mg twice per day. Elagolix is metabolized in the liver, with the major pathway being by CYP3A and minor pathways including by CYP2D6, CYP2C8, and UDP-glucuronosyltransferases.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Is TB-500 identical to thymosin beta-4?

Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.

Is TB-500 an approved medicine?

No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.

How is the peptide detected in samples?

The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.

Network